Related Experiment Video
Updated: Jun 10, 2026
Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
Published on: June 4, 2017
Eradication of brain tumor stem cells with an oncolytic adenovirus
1Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. hjiang@mdanderson.org
Abstract:
Malignant gliomas, the most common type of primary brain tumors, are one of the most deadly cancers. Even when given the best available treatment, patients with these tumors face a poor prognosis, a situation that has changed little in the past several decades. Recently, researchers identified brain tumor stem cells that are responsible for tumors' resistance to therapy and recurrence. Since conventional radiotherapy and chemotherapy have had limited success in the treatment of malignant gliomas, we developed an oncolytic adenovirus, Delta-24-RGD, that is able to efficiently eradicate both brain tumor bulk and stem cells, indicating its potential to induce complete tumor remission in patients with malignant gliomas. Currently, this novel agent is being tested in a phase I clinical trial at the Brain Tumor Center, The University of Texas MD Anderson Cancer Center.
Insights
Researchers developed Delta-24-RGD, an oncolytic adenovirus, to target malignant gliomas and brain tumor stem cells. This novel therapy shows potential for complete tumor remission in patients with these deadly brain cancers.
Area of Science:
- Neuro-oncology
- Virology
- Cancer Stem Cell Biology
Background:
- Malignant gliomas are aggressive primary brain tumors with poor patient prognosis.
- Recurrence and therapy resistance are linked to brain tumor stem cells.
- Conventional treatments like radiotherapy and chemotherapy show limited efficacy.
Purpose of the Study:
- To develop a novel therapeutic agent for malignant gliomas.
- To target both the bulk tumor and the therapy-resistant brain tumor stem cells.
- To evaluate the potential of oncolytic virotherapy for complete tumor remission.
Main Methods:
- Development of an oncolytic adenovirus, Delta-24-RGD.
- Assessment of the agent's efficacy against malignant glioma cells and brain tumor stem cells.
- Initiation of a phase I clinical trial to evaluate safety and preliminary efficacy.
Main Results:
- Delta-24-RGD demonstrates efficient eradication of both glioma bulk and stem cells.
- The oncolytic adenovirus shows potential for inducing complete tumor remission.
- A phase I clinical trial is currently underway to assess the agent in patients.
Conclusions:
- Oncolytic adenovirus Delta-24-RGD is a promising therapeutic strategy for malignant gliomas.
- Targeting brain tumor stem cells is crucial for overcoming treatment resistance.
- Further clinical investigation is warranted to establish the efficacy of Delta-24-RGD.
